Results by group95

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 95

Download this page as JSON

Outcome	Group	Category	Value	Units
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period	Lanadelumab 300 mg Q2W	Any TEAEs: Non-Angioedema Attack	55	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period	Lanadelumab 300 mg Q4W	Any TEAEs: Non-Angioedema Attack	1	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period	Lanadelumab 300 mg Q2W	Any TEAEs: Angioedema Attack	61	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period	Lanadelumab 300 mg Q4W	Any TEAEs: Angioedema Attack	1	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period	Lanadelumab 300 mg Q2W	AESI: Non-Angioedema Attack	1	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period	Lanadelumab 300 mg Q4W	AESI: Non-Angioedema Attack	0	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period	Lanadelumab 300 mg Q2W	AESI: Angioedema Attack	0	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period	Lanadelumab 300 mg Q4W	AESI: Angioedema Attack	0	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period	Lanadelumab 300 mg Q2W	Any SAEs: Non-Angioedema Attack	5	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period	Lanadelumab 300 mg Q4W	Any SAEs: Non-Angioedema Attack	1	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period	Lanadelumab 300 mg Q2W	Any SAEs: Angioedema Attack	3	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period	Lanadelumab 300 mg Q4W	Any SAEs: Angioedema Attack	0	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Follow-up	Lanadelumab 300 mg Q2W	Any TEAEs: Non-Angioedema Attack	4	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Follow-up	Lanadelumab 300 mg Q4W	Any TEAEs: Non-Angioedema Attack	0	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Follow-up	Lanadelumab 300 mg Q2W	Any TEAEs: Angioedema Attack	19	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Follow-up	Lanadelumab 300 mg Q4W	Any TEAEs: Angioedema Attack	0	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Follow-up	Lanadelumab 300 mg Q2W	AESI: Non-Angioedema Attack	0	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Follow-up	Lanadelumab 300 mg Q4W	AESI: Non-Angioedema Attack	0	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Follow-up	Lanadelumab 300 mg Q2W	AESI: Angioedema Attack	0	Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Follow-up	Lanadelumab 300 mg Q4W	AESI: Angioedema Attack	0	Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04444895/results

API reference For AI assistants

Results by group95

Sources 3

Read this list from software.